Akero Therapeutics, Inc. (NASDAQ:AKRO)

About the company

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

13

CEO

Andrew Cheng

Exchange

NASDAQ

Website

http://www.akerotx.com

$NoneM

Total Revenue

13

Employees

$1B

Market Capitalization

-21.53

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Johnson & Johnson JNJ 381124.48 82729.00 6.12 22.21 20.75
Merck & Co., Inc. MRK 196889.19 48081.00 7.39 19.43 21.10
Pfizer Inc. PFE 190835.04 50660.00 2.89 12.08 31.17
Eli Lilly & Co. LLY 149964.48 23087.00 50.89 26.43 23.97
AbbVie, Inc. ABBV 143695.72 34057.00 -23.00 17.14 24.65
Bristol Myers Squibb Co. BMY 107221.81 31006.00 2.60 91.16 3.08
Repligen Corp. RGEN 6432.63 286.00 6.17 280.29 8.11
Reata Pharmaceuticals, Inc. RETA 4786.40 20.00 22.67 -15.39 -150.30
Nektar Therapeutics NKTR 4229.28 137.00 3.30 -9.21 -335.62
Biohaven Pharmaceutical Holding Co. Ltd. BHVN 3855.28 1.00 35.64 -5.90 None
Allakos, Inc. ALLK 3213.86 None 6.98 -34.36 None
Karuna Therapeutics, Inc. KRTX 2485.08 None 6.49 -61.27 None
OPKO Health, Inc. OPK 2448.18 891.00 1.74 -8.37 -32.92
ADC Therapeutics SA ADCT 2343.60 2.00 27.64 -20.09 None
IGM Biosciences, Inc. IGMS 2191.70 None 9.66 -40.40 None
Turning Point Therapeutics, Inc. TPTX 2173.68 None 6.54 -18.19 None
Apellis Pharmaceuticals, Inc. APLS 2141.70 None 9.46 -5.13 None
Ra Pharmaceuticals, Inc. RARX 2111.78 3.00 8.68 -20.78 -585.71
Principia Biopharma, Inc. PRNB 1792.84 30.00 6.38 -25.51 -242.01
Springworks Therapeutics, Inc. SWTX 1651.20 None 5.36 -26.48 None
Y-mAbs Therapeutics, Inc. YMAB 1477.04 None 9.05 -16.03 None
Zymeworks, Inc. ZYME 1393.98 26.00 2.89 -8.22 -629.37
Tricida, Inc. TCDA 1300.46 None 6.69 -6.16 None
Akcea Therapeutics, Inc. AKCA 1261.97 341.00 2.59 -44.86 -8.59
Kiniksa Pharmaceuticals Ltd. KNSA 1223.75 None 6.34 -10.11 None
Odonate Therapeutics, Inc. ODT 1127.52 None 9.24 -10.02 None
Akero Therapeutics, Inc. AKRO 1092.43 None 9.12 -21.53 None
Arcutis Biotherapeutics, Inc. ARQT 1076.33 None 4.59 -17.21 None
Phibro Animal Health Corp. PAHC 1029.10 818.00 5.20 27.89 4.49
Athenex, Inc. ATNX 971.88 123.00 5.96 -9.03 -87.86
Constellation Pharmaceuticals, Inc. CNST 944.96 None 4.45 -10.18 None
Gossamer Bio, Inc. GOSS 798.49 None 3.24 -4.02 None
G1 Therapeutics, Inc. GTHX 774.63 1.00 3.35 -5.91 None
Quanterix Corp. QTRX 736.56 60.00 6.50 -16.84 -71.52
Phathom Pharmaceuticals, Inc. PHAT 731.00 None 4.06 -2.69 None
Krystal Biotech, Inc. KRYS 695.98 None 4.06 -33.56 None
Oric Pharmaceuticals, Inc. ORIC 691.88 None -7.51 -22.88 None
Applied Therapeutics, Inc. APLT 670.34 14.00 4.33 -13.60 -19.41
Provention Bio, Inc. PRVB 669.94 None 10.60 -15.13 None
Provention Bio, Inc. PRVB 651.88 None 10.31 -14.72 None
Amneal Pharmaceuticals, Inc. AMRX 637.05 1679.00 4.39 -2.92 -11.85
Arcturus Therapeutics Holdings, Inc. ARCT 632.06 19.00 58.58 -22.72 -151.34
Aprea Therapeutics, Inc. APRE 617.82 None 5.47 -18.27 None
Keros Therapeutics, Inc. KROS 601.74 8.00 -27.18 -28.33 -285.35
Oyster Point Pharma, Inc. OYST 534.45 None 5.37 -9.29 None
Mirum Pharmaceuticals, Inc. MIRM 491.75 None 3.20 -7.26 None
SIGA Technologies, Inc. SIGA 467.40 19.00 5.23 -23.75 -94.00
89bio, Inc. ETNB 451.08 None 5.56 -6.99 None
Fulcrum Therapeutics, Inc. FULC 445.97 1.00 7.52 -6.46 None
Osmotica Pharmaceuticals Plc OSMT 442.80 232.00 3.36 -1.61 -115.44
Biospecifics Technologies Corp. BSTC 442.47 40.00 3.59 18.93 61.80
Satsuma Pharmaceuticals, Inc. STSA 437.75 None 4.31 -12.03 None
Imara, Inc. IMRA 424.15 None 4.10 -12.05 None
DURECT Corp. DRRX 390.60 28.00 30.00 -16.15 -82.94
TCR2 Therapeutics, Inc. TCRR 383.04 None 2.62 -38.00 None
Relmada Therapeutics, Inc. RLMD 380.97 0.00 5.68 -31.83 -877.66
Crinetics Pharmaceuticals, Inc. CRNX 366.96 1.00 4.63 -6.29 -447.78
Kala Pharmaceuticals, Inc. KALA 365.76 6.00 4.00 -3.98 None
Ocular Therapeutix, Inc. OCUL 356.16 6.00 -43.65 -3.88 None
Ovid Therapeutics, Inc. OVID 336.15 None 7.95 -5.15 None
Aeglea Biotherapeutics, Inc. AGLE 292.05 4.00 9.22 -3.64 -523.27
Gritstone Oncology, Inc. GRTS 291.24 4.00 2.61 -2.79 None
Urovant Sciences Ltd. UROV 281.70 None -4.99 -1.95 None
HOOKIPA Pharma, Inc. HOOK 268.32 13.00 2.43 -5.93 -333.02
IDEAYA Biosciences, Inc. IDYA 266.80 None 4.05 -6.12 None
Spero Therapeutics, Inc. SPRO 247.38 12.00 3.26 -3.04 -656.72
AMAG Pharmaceuticals, Inc. AMAG 246.84 321.00 0.94 -0.67 -115.05
Verrica Pharmaceuticals, Inc. VRCA 238.50 None 4.36 -7.82 None
KalVista Pharmaceuticals, Inc. KALV 221.58 12.00 2.45 -6.84 -263.38
Lannett Co., Inc. LCI 218.12 542.00 0.75 -7.17 -5.77
Kaleido Biosciences, Inc. KLDO 202.80 None 7.19 -2.77 None
Sutro Biopharma, Inc. STRO 200.79 41.00 3.81 -3.29 -148.06
Veru, Inc. VERU 198.90 39.00 6.65 -20.40 -25.53
Galera Therapeutics, Inc. GRTX 179.50 None 3.36 -2.73 None
LogicBio Therapeutics, Inc. LOGC 177.79 1.00 5.37 -4.18 None
Protara Therapeutics, Inc. TARA 164.52 None 2.47 -10.67 None
Liquidia Technologies, Inc. LQDA 163.68 8.00 12.83 -3.32 -602.17
Avenue Therapeutics, Inc. ATXI 156.00 532.00 28.68 -10.71 26.69
Lyra Therapeutics, Inc. LYRA 150.84 1.00 -1.28 -9.04 -491.16
Cyclerion Therapeutics, Inc. CYCN 145.26 6.00 1.83 -1.40 None
scPharmaceuticals, Inc. SCPH 144.97 119.00 3.70 -4.62 -27.05
Tyme Technologies, Inc. TYME 140.30 None 8.13 -6.42 None
PhaseBio Pharmaceuticals, Inc. PHAS 137.17 2.00 2.54 -2.87 None
Evelo Biosciences, Inc. EVLO 134.40 None 4.94 -1.53 None
Harrow Health, Inc. HROW 130.26 51.00 8.35 -5.27 -47.54
Corvus Pharmaceuticals, Inc. CRVS 127.60 None 2.05 -2.70 None
Mustang Bio, Inc. MBIO 125.60 None 2.93 -2.55 None
TFF Pharmaceuticals, Inc. TFFP 122.36 None 4.74 -3.16 None
Aquestive Therapeutics, Inc. AQST 120.12 49.00 -6.92 -1.71 -139.64
Ayala Pharmaceuticals, Inc. AYLA 120.00 3.00 -2.82 -5.81 -679.19
Immunic, Inc. IMUX 117.40 None 3.45 -53.36 None
NeuBase Therapeutics, Inc. NBSE 116.06 None 48.76 -2.60 None
Trevi Therapeutics, Inc. TRVI 104.76 None 2.22 -3.57 None
Evolus, Inc. EOLS 96.00 45.00 1.72 -0.95 -217.51
Milestone Pharmaceuticals, Inc. MIST 92.25 None 0.91 -1.48 None
Eton Pharmaceuticals, Inc. ETON 90.90 1.00 9.90 -4.55 None
EyePoint Pharmaceuticals, Inc. EYPT 81.75 26.00 5.77 -1.67 -196.30
Xeris Pharmaceuticals, Inc. XERS 72.24 4.00 3.58 -0.56 None
Clearside Biomedical, Inc. CLSD 71.34 6.00 9.16 -4.05 -293.61
Checkpoint Therapeutics, Inc. CKPT 70.80 2.00 6.10 -3.05 -949.53
Navidea Biopharmaceuticals, Inc. NAVB 68.85 1.00 -50.63 -6.23 -65.13
Baudax Bio, Inc. BXRX 63.54 None -1.73 -0.91 None
Genprex, Inc. GNPX 59.09 None 5.02 -4.32 None
BiomX, Inc. PHGE 58.74 None 1.55 -1.37 None
Aridis Pharmaceuticals, Inc. ARDS 58.50 1.00 -24.07 -2.00 -851.00
Assertio Therapeutics, Inc. ASRT 58.32 192.00 1.01 -0.36 -83.99
Aerpio Pharmaceuticals, Inc. ARPO 51.66 20.00 1.56 -2.74 -51.58
Menlo Therapeutics, Inc. MNLO 48.72 2.00 4.10 -0.52 -483.51
Edesa Biotech, Inc. EDSA 43.29 0.00 6.17 -0.46 -395.23
Eyenovia, Inc. EYEN 42.56 None 4.29 -2.08 None
Annovis Bio, Inc. ANVS 42.49 None 3.89 -33.72 None
Moleculin Biotech, Inc. MBRX 39.38 None 3.42 -4.28 None
Citius Pharmaceuticals, Inc. CTXR 36.18 None 2.68 -2.09 None
Akari Therapeutics Plc AKTX 36.18 None -33.50 -2.01 None
Acer Therapeutics, Inc. ACER 35.00 3.00 2.55 -1.34 -274.69
AgeX Therapeutics, Inc. AGE 34.88 2.00 -45.90 -2.87 -658.11
Mannatech, Inc. MTEX 34.80 156.00 1.47 7.84 3.45
Adamis Pharmaceuticals Corp. ADMP 33.64 22.00 1.29 -1.14 -140.33
Allena Pharmaceuticals, Inc. ALNA 33.35 None 4.39 -0.77 None
Aileron Therapeutics, Inc. ALRN 29.96 None 4.12 -1.13 None
CNS Pharmaceuticals, Inc. CNSP 29.92 None 5.19 -5.50 None
Oncternal Therapeutics, Inc. ONCT 28.99 3.00 3.72 -1.15 -225.89
Millendo Therapeutics, Inc. MLND 25.95 0.00 0.61 -0.55 None
Hoth Therapeutics, Inc. HOTH 25.40 None 7.06 -2.82 None
Spring Bank Pharmaceuticals, Inc. SBPH 23.52 0.00 0.89 -0.90 None
Akorn, Inc. AKRX 22.68 721.00 -1.20 -0.06 -55.64
Daré Bioscience, Inc. DARE 19.76 1.00 8.67 -1.18 None
ProPhase Labs, Inc. PRPH 18.96 9.00 1.72 -6.32 -31.15
Novan, Inc. NOVN 14.82 5.00 -3.41 -0.47 -602.34
Adial Pharmaceuticals, Inc. ADIL 14.80 None 3.61 -1.95 None
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
PDS Biotechnology Corp. PDSB 14.14 None 1.57 -0.55 None
Titan Pharmaceuticals, Inc. TTNP 11.60 4.00 4.83 -0.64 -437.91
Novus Therapeutics, Inc. NVUS 7.74 None 0.66 -0.37 None
Brickell Biotech, Inc. BBI 4.66 5.00 1.53 -0.06 -432.19
BioStar Pharmaceuticals, Inc. BSPM 0.21 0.00 0.01 0.10 294.01

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

4d ago, source: PR Newswire

PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company ...

Stock Alert: Akero Therapeutics Up 31%

10d ago, source: Nasdaq

(RTTNews) - Akero Therapeutics, Inc. (AKRO) shares are rising on Wednesday as it reported a positive result in its phase 2a ...

After Market Hours: Akero Therapeutics, FedEx, Carver Bancorp Jump; Chiasma, Steelcase Slip

11d ago, source: Nasdaq

Shares of the clinical-stage biotechnology company jumped over 50% in after hours on Tuesday. The company announced positive ...

In race to defeat fatty liver disease, Peninsula biotech lines up next clinical trial

1d ago, source: The Business Journals

In the race to find a drug for the fatty liver disease NASH, George Kemble isn’t dissuaded by Sagimet Biosciences’ size; it’s ...

BRIEF-Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups In Nash Patients

11d ago, source: Reuters

AKERO ANNOUNCES STRONGLY POSITIVE HISTOLOGICAL DATA ACROSS ALL EFRUXIFERMIN DOSE GROUPS IN 16-WEEK PHASE 2A BALANCED STUDY IN NASH PATIENTS * AKERO THERAPEUTICS INC - TREATMENT WITH EFX WAS GENERALLY ...

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

9d ago, source: Stockhouse

Clinical-stage biotechnology company Akero Therapeutics Inc. (AKRO:NASDAQ), which develops and commercializes treatments for serious metabolic diseases, yesterday announced "results of a 16-week ...

Why Akero's Liver (NASH) Treatment Could Take This Stock Much Higher

9d ago, source: 24/7 Wall St on MSN.com

A main highlight of the report was that of the 40 treatment responders who had end-of-treatment biopsies, 48% achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.